SBIR PHASE II TOPIC 294:SITE-SPECIFIC ANTIBODIES FOR GLCNACYLATED PROTEINS IN CANCER; HHSN261201300058C; POP: 9/13/13-09/12/16; CAN: 8478363 IGF::OT::IGF OTHER FUNCTIONS
Award amount
$10,338Program and phase
SBIR · Phase IIAward year
2019Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- DETROIT R & D, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- N7KSKX4HJA58
- Solicitation number
- Not reported
- Topic code
- NCI
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- IGF OT IGF Circulating nucleic acid based nanowell label free array technology in cancer
- SBIR PHASE II TOPIC 294:SITE-SPECIFIC ANTIBODIES FOR GLCNACYLATED PROTEINS IN CAN
- Glycoproteins and Glycan-Binding IgGs: Biomarkers for Cancer and Inflammatory Di
- SBIR TOPIC 294 PHASE I - DEVELOPMENT OF GLYCOSYLATION-SPECIFIC RESEARCH REAGENTS (ANTIBODIES AND APTAMERS)
- Not Available
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis
Research funding history
18 SBIR/STTR records share this UEI (1998–2019). Reported award amounts total $5,013,748. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services